IV administration of endothelin B receptor drug reduces memory loss, oxidative stress in Alzheimer's disease
Friday, September 4, 2015 - 15:00
in Health & Medicine
An estimated 5.3 million people in the U.S. suffer from Alzheimer’s disease (AD). The five current FDA-approved AD medications only help mask the disease symptoms instead of treating the underlying disease. In a new study, researchers used IRL-1620, a chemical that binds to endothelin B receptors, to treat AD in rats.